Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04828616
What this trial is testing

Study of DP303c Injection in Patients With Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 104
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Testing effectiveness (Phase 2)UnknownNCT06233864
What this trial is testing

The Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sun Yat-sen University 63
Testing effectiveness (Phase 2)Looking for participantsNCT07192432
What this trial is testing

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Who this might be right for
HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc. 27
Testing effectiveness (Phase 2)Study completedNCT01997333
What this trial is testing

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Who this might be right for
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Celldex Therapeutics 327
Testing effectiveness (Phase 2)UnknownNCT05601401
What this trial is testing

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Who this might be right for
Salivary Gland Tumors
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT06966453
What this trial is testing

Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Who this might be right for
Breast CancerBreast Neoplasms
Pfizer 74
Testing effectiveness (Phase 2)Study completedNCT03925974
What this trial is testing

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Gastric/Gastroesophageal Junction Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 45
Early research (Phase 1)Active Not RecruitingNCT06746688
What this trial is testing

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

Who this might be right for
Breast CancerBreast Cancer Metastatic
ExpreS2ion Biotechnologies 40
Not applicableStudy completedNCT06168227
What this trial is testing

And Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 150
Large-scale testing (Phase 3)Not Yet RecruitingNCT07608224
What this trial is testing

HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC

Who this might be right for
Urinary Bladder Neoplasms
West China Hospital 240
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Early research (Phase 1)Study completedNCT04246671
What this trial is testing

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Who this might be right for
ChordomaHER2-positive Breast Cancer
Bavarian Nordic 37
Large-scale testing (Phase 3)Ended earlyNCT01613482
What this trial is testing

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Who this might be right for
Breast CancerMetastasisSur-expressing Her2-neu
Centre Oscar Lambret 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 59
Not applicableLooking for participantsNCT07358182
What this trial is testing

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Who this might be right for
Trastuzumab-rezetecanHER2-low Breast CancerHER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Large-scale testing (Phase 3)Not Yet RecruitingNCT07545460
What this trial is testing

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 404
Testing effectiveness (Phase 2)Study completedNCT01570036
What this trial is testing

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Who this might be right for
Breast Cancer
George E. Peoples 275
Early research (Phase 1)UnknownNCT06254807
What this trial is testing

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positive
Carisma Therapeutics Inc 6
Next Page